Review: Pharmacokinetics and pharmacodynamics of the taxanes

Yui-wing F Lam, Jennifer C Y Chan, John G. Kuhn

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives. To review the pharmacokinetics and pharmacodynamics of docetaxel and paclitaxel. Data Sources. We reviewed the literature through a MEDLINE search from 1982 to 1996. The terms docetaxel, paclitaxel, taxanes, and taxoids were used in the search. Relevant articles cited in literature obtained by MEDLINE searching, as well as new articles published in early 1997 in specific oncology journals, were also considered. Data Extraction. We have reviewed the current literature with regard to the chemistry, mechanisms of action and pharmacology, pharmacokinetics, clini cal use, adverse effects, drug interactions, formula tion, dosage, administration, and pharmaceutical is sues of the taxanes. Conclusion. Both docetaxel and paclitaxel are novel antineoplastic agents with significant activity in many types of cancer. The pharmacokinetics of both agents are best characterized by a three-compartment disposition profile. However, the pharmacokinetics of paclitaxel, not docetaxel, are non-linear and can be described by a saturation process in distribution and elimination. The nonlinearity appears to be associated more frequently with shorter infusions and/or higher doses. There is evidence suggesting that the time duration of paclitaxel concentrations maintained above 0.1 μM/L (T>0.1 μM) is associated with improved survival and development of toxicity. On the other hand, currently there is no information relating opti mal systemic exposure of docetaxel to efficacy and toxicity. In addition, these pharmacokinetic-pharma codynamic relationship may change with therapy with antineoplastic agents and other agents adminis tered concurrently, and necessitates additional phar macokinetic-pharmacodynamic investigations.

Original languageEnglish (US)
Pages (from-to)76-93
Number of pages18
JournalJournal of Oncology Pharmacy Practice
Volume3
Issue number2
DOIs
StatePublished - 1997

Fingerprint

docetaxel
Taxoids
Paclitaxel
Pharmacokinetics
MEDLINE
Antineoplastic Agents
Information Storage and Retrieval
Drug Interactions
Pharmacology

Keywords

  • Docetaxel
  • Paclitaxel
  • Pharmaco-dynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Review : Pharmacokinetics and pharmacodynamics of the taxanes. / Lam, Yui-wing F; Chan, Jennifer C Y; Kuhn, John G.

In: Journal of Oncology Pharmacy Practice, Vol. 3, No. 2, 1997, p. 76-93.

Research output: Contribution to journalArticle

Lam, Yui-wing F ; Chan, Jennifer C Y ; Kuhn, John G. / Review : Pharmacokinetics and pharmacodynamics of the taxanes. In: Journal of Oncology Pharmacy Practice. 1997 ; Vol. 3, No. 2. pp. 76-93.
@article{a4c1d8e194f64e8cb50628448b427994,
title = "Review: Pharmacokinetics and pharmacodynamics of the taxanes",
abstract = "Objectives. To review the pharmacokinetics and pharmacodynamics of docetaxel and paclitaxel. Data Sources. We reviewed the literature through a MEDLINE search from 1982 to 1996. The terms docetaxel, paclitaxel, taxanes, and taxoids were used in the search. Relevant articles cited in literature obtained by MEDLINE searching, as well as new articles published in early 1997 in specific oncology journals, were also considered. Data Extraction. We have reviewed the current literature with regard to the chemistry, mechanisms of action and pharmacology, pharmacokinetics, clini cal use, adverse effects, drug interactions, formula tion, dosage, administration, and pharmaceutical is sues of the taxanes. Conclusion. Both docetaxel and paclitaxel are novel antineoplastic agents with significant activity in many types of cancer. The pharmacokinetics of both agents are best characterized by a three-compartment disposition profile. However, the pharmacokinetics of paclitaxel, not docetaxel, are non-linear and can be described by a saturation process in distribution and elimination. The nonlinearity appears to be associated more frequently with shorter infusions and/or higher doses. There is evidence suggesting that the time duration of paclitaxel concentrations maintained above 0.1 μM/L (T>0.1 μM) is associated with improved survival and development of toxicity. On the other hand, currently there is no information relating opti mal systemic exposure of docetaxel to efficacy and toxicity. In addition, these pharmacokinetic-pharma codynamic relationship may change with therapy with antineoplastic agents and other agents adminis tered concurrently, and necessitates additional phar macokinetic-pharmacodynamic investigations.",
keywords = "Docetaxel, Paclitaxel, Pharmaco-dynamics, Pharmacokinetics",
author = "Lam, {Yui-wing F} and Chan, {Jennifer C Y} and Kuhn, {John G.}",
year = "1997",
doi = "10.1177/107815529700300202",
language = "English (US)",
volume = "3",
pages = "76--93",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Review

T2 - Pharmacokinetics and pharmacodynamics of the taxanes

AU - Lam, Yui-wing F

AU - Chan, Jennifer C Y

AU - Kuhn, John G.

PY - 1997

Y1 - 1997

N2 - Objectives. To review the pharmacokinetics and pharmacodynamics of docetaxel and paclitaxel. Data Sources. We reviewed the literature through a MEDLINE search from 1982 to 1996. The terms docetaxel, paclitaxel, taxanes, and taxoids were used in the search. Relevant articles cited in literature obtained by MEDLINE searching, as well as new articles published in early 1997 in specific oncology journals, were also considered. Data Extraction. We have reviewed the current literature with regard to the chemistry, mechanisms of action and pharmacology, pharmacokinetics, clini cal use, adverse effects, drug interactions, formula tion, dosage, administration, and pharmaceutical is sues of the taxanes. Conclusion. Both docetaxel and paclitaxel are novel antineoplastic agents with significant activity in many types of cancer. The pharmacokinetics of both agents are best characterized by a three-compartment disposition profile. However, the pharmacokinetics of paclitaxel, not docetaxel, are non-linear and can be described by a saturation process in distribution and elimination. The nonlinearity appears to be associated more frequently with shorter infusions and/or higher doses. There is evidence suggesting that the time duration of paclitaxel concentrations maintained above 0.1 μM/L (T>0.1 μM) is associated with improved survival and development of toxicity. On the other hand, currently there is no information relating opti mal systemic exposure of docetaxel to efficacy and toxicity. In addition, these pharmacokinetic-pharma codynamic relationship may change with therapy with antineoplastic agents and other agents adminis tered concurrently, and necessitates additional phar macokinetic-pharmacodynamic investigations.

AB - Objectives. To review the pharmacokinetics and pharmacodynamics of docetaxel and paclitaxel. Data Sources. We reviewed the literature through a MEDLINE search from 1982 to 1996. The terms docetaxel, paclitaxel, taxanes, and taxoids were used in the search. Relevant articles cited in literature obtained by MEDLINE searching, as well as new articles published in early 1997 in specific oncology journals, were also considered. Data Extraction. We have reviewed the current literature with regard to the chemistry, mechanisms of action and pharmacology, pharmacokinetics, clini cal use, adverse effects, drug interactions, formula tion, dosage, administration, and pharmaceutical is sues of the taxanes. Conclusion. Both docetaxel and paclitaxel are novel antineoplastic agents with significant activity in many types of cancer. The pharmacokinetics of both agents are best characterized by a three-compartment disposition profile. However, the pharmacokinetics of paclitaxel, not docetaxel, are non-linear and can be described by a saturation process in distribution and elimination. The nonlinearity appears to be associated more frequently with shorter infusions and/or higher doses. There is evidence suggesting that the time duration of paclitaxel concentrations maintained above 0.1 μM/L (T>0.1 μM) is associated with improved survival and development of toxicity. On the other hand, currently there is no information relating opti mal systemic exposure of docetaxel to efficacy and toxicity. In addition, these pharmacokinetic-pharma codynamic relationship may change with therapy with antineoplastic agents and other agents adminis tered concurrently, and necessitates additional phar macokinetic-pharmacodynamic investigations.

KW - Docetaxel

KW - Paclitaxel

KW - Pharmaco-dynamics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0002393030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002393030&partnerID=8YFLogxK

U2 - 10.1177/107815529700300202

DO - 10.1177/107815529700300202

M3 - Article

AN - SCOPUS:0002393030

VL - 3

SP - 76

EP - 93

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

IS - 2

ER -